查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1890922

脑肿瘤治疗市场：依治疗方法、肿瘤类型、药物分类、年龄层、性别、最终用户、通路和地区划分

Brain Tumor Treatment Market, By Treatment Modality, By Tumor Type, By Drug Class, By Age Group, By Gender, By End User, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2025 年，脑肿瘤治疗市场价值将达到 23.4 亿美元，到 2032 年将达到 45.3 亿美元，2025 年至 2032 年的复合年增长率为 9.9%。

报告覆盖范围 报告详情
基准年： 2024 2025年市场规模： 23.4亿美元
历史数据时期： 2020年至2024年 预测期： 2025年至2032年
预测期（2025-2032年）复合年增长率： 9.90% 预计2032年价值： 45.3亿美元

全球脑肿瘤治疗市场是更广泛的肿瘤治疗领域中的重要细分市场，它致力于解决影响中枢神经系统的最复杂、最具挑战性的疾病之一。

脑肿瘤的特征是脑组织内或周围的细胞异常增生，包括起源于脑部的原发性肿瘤和从其他部位转移而来的继发次发性肿瘤。治疗方案采用多管齐下的方法，结合手术、放射线治疗、化疗、标靶治疗和新兴的免疫疗法，每种疗法都根据特定的肿瘤类型、原发部位和患者病情量身定制。

该市场的重要性不仅限于传统治疗方法，还涵盖立体定位放射放射线手术、肿瘤电场治疗以及基于分子谱分析的个人化医疗等先进技术。全球脑肿瘤发生率的上升、人口老化以及诊断技术的进步，都在推动对有效治疗方案的需求。

人工智慧融入治疗方案製定、血脑障壁渗透性药物的研发以及微创手术技术的进步正在重塑治疗通讯协定。世界各地的医疗系统都在加大对神经肿瘤专科中心和尖端设备的投入，而製药公司也在加速研发，以满足这一充满挑战的治疗领域尚未满足的医疗需求。

市场动态

全球脑肿瘤治疗市场受多种强劲因素驱动，持续塑造其成长轨迹，同时也面临一些显着的限制因素，为相关人员带来了巨大的机会。主要市场驱动因素包括：全球各年龄层脑肿瘤发生率的不断上升；老年人口的增长（老年人尤其容易患各种类型的肿瘤）；以及患者和医疗保健提供者对早期诊断和治疗方案的认识不断提高。

高解析度磁振造影（MRI）、正子断层扫描（PET）和分子诊断等先进诊断技术能够更早、更准确地发现肿瘤，从而推动了治疗需求。标靶治疗、免疫疗法和基于基因谱的个人化医疗等新型治疗方法的快速发展，正在拓展治疗选择，改善患者预后。然而，脑肿瘤治疗费用极高仍是一个主要阻碍因素。治疗通常需要漫长而复杂的治疗方案、专用医疗设备以及长期住院，这给患者和医疗系统都带来了沉重的经济负担。

血脑障壁是一项重大的生物学挑战，它限制了药物输送的有效性，并缩小了治疗选择范围。此外，脑肿瘤复杂的解剖位置使得手术介入本身就风险极高，有时甚至根本无法进行。新治疗方法的严格监管核准流程以及罕见脑肿瘤患者群体相对较小的特点，都给製药公司带来了额外的挑战。

本次调查的主要特点

  • 本报告对全球脑肿瘤治疗市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和復合年增长率百分比。
  • 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
  • 该研究根据以下参数对全球脑肿瘤治疗市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
  • 本研究主要企业包括：罗氏製药有限公司、诺华製药有限公司、默克公司、辉瑞公司、拜耳公司、卫材株式会社、百时美施贵宝公司、安进公司、葛兰素史克公司、强生公司、阿斯特捷利康公司、y-Mabs Therapeutics公司、Emcure Pharmaceuticals 有限公司、Nextuticalceticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals）公司。
  • 本报告的研究结果将使负责人和经营团队能够就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
  • 这份全球脑肿瘤治疗市场报告的目标受众包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 相关人员可以透过各种用于分析全球脑肿瘤治疗市场的策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场范围

  • 报告概述
    • 市场定义和范围
  • 执行摘要

第三章 市场动态、监管与趋势分析

  • 市场动态
  • 司机
  • 抑制因素
  • 机会
  • 影响分析
  • 重大进展
  • 法规环境
  • 产品上市及核准
  • PEST分析
  • 波特分析
  • 併购趋势
  • 产业趋势

4. 2020-2032年全球脑肿瘤治疗市场（依治疗方法）

  • 化疗（例如，烷化剂、细胞毒性药物）
  • 放射线治疗（例如体外放射治疗、立体定位放射线手术）
  • 标靶治疗（例如，分子标靶小分子化合物）
  • 免疫疗法（例如，查核点抑制剂、CAR-T疗法）
  • 其他治疗方法（例如，肿瘤治疗电场疗法、基因疗法、联合治疗）

5. 2020-2032年全球脑肿瘤治疗市场（依肿瘤类型划分）

  • 原发性脑瘤（例如，胶质母细胞瘤、星状细胞瘤）
  • 转移性/次发性脑肿瘤
  • 脑膜瘤
  • 脑下垂体瘤
  • 其他肿瘤类型（例如少突胶质细胞瘤、室管膜瘤）

6. 2020-2032年全球脑肿瘤治疗市场（依药物分类）

  • 烷化剂
  • 抗代谢物
  • 单株抗体
  • 小分子抑制剂
  • 其他药物类别（例如，蛋白酶体抑制剂、表观遗传调节剂）

7. 2020-2032年全球脑肿瘤治疗市场（依年龄层划分）

  • 儿童
  • 成人
  • 老年人

8. 2020-2032年全球脑肿瘤治疗市场（依性别划分）

  • 男性
  • 女士

9. 2020-2032年全球脑肿瘤治疗市场（依最终使用者划分）

  • 医院及综合癌症中心
  • 门诊手术中心/门诊护理中心
  • 专科诊所（神经肿瘤科诊所）
  • 居家医疗/远端医疗环境（如适用）

第十章 全球脑肿瘤治疗市场（依通路划分），2020-2032年

  • 医院药房
  • 零售药房
  • 网路药房

第十一章 2020-2032年全球脑肿瘤治疗市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十二章 竞争格局

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals plc
  • Sun Pharmaceutical Industries Ltd.
  • Johnson and Johnson
  • Viatris Inc.
  • Hikma Pharmaceuticals plc
  • Aurobindo Pharma Ltd.
  • Endo International plc
  • Mylana€¯NV（现为 Viatris）
  • 默克集团
  • BristolMyers Squibb Company
  • Grunenthal GmbH
  • Sanofi SA
  • AbbVie Inc.

第十三章 分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map

第十四章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI8946

Brain Tumor Treatment Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 4.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 2.34 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.90% 2032 Value Projection: USD 4.53 Bn

The global brain tumor treatment market represents a critical segment within the broader oncology therapeutics landscape, addressing one of the most complex and challenging medical conditions affecting the central nervous system.

Brain tumors, characterized by abnormal cell growth within or around the brain tissue, encompass both primary tumors originating in the brain and secondary metastatic tumors spreading from other body parts. The treatment paradigm involves a multidisciplinary approach combining surgical interventions, radiation therapy, chemotherapy, targeted therapy, and emerging immunotherapy options, each tailored to specific tumor types, locations, and patient conditions.

The market's significance extends beyond traditional therapeutic modalities, incorporating advanced technologies such as stereotactic radiosurgery, tumor-treating fields, and personalized medicine approaches based on molecular profiling. Rising incidence rates of brain tumors globally, coupled with an aging population and improved diagnostic capabilities, have intensified the demand for effective treatment solutions.

The integration of artificial intelligence in treatment planning, development of blood-brain barrier penetrating drugs, and advancement in minimally invasive surgical techniques are reshaping treatment protocols. Healthcare systems worldwide are increasingly investing in specialized neuro-oncology centers and cutting-edge equipment, while pharmaceutical companies are accelerating research and development efforts to address unmet medical needs in this challenging therapeutic area.

Market Dynamics

The global brain tumor treatment market is propelled by several compelling drivers that continue to shape its growth trajectory, while simultaneously facing notable restraints and presenting significant opportunities for stakeholders. The primary market drivers include the escalating global incidence of brain tumors across all age groups, with particular emphasis on the growing geriatric population that exhibits higher susceptibility to various tumor types, alongside increasing awareness about early diagnosis and treatment options among patients and healthcare providers.

Advanced diagnostic technologies such as high-resolution MRI, PET scans, and molecular diagnostics are enabling earlier and more precise tumor detection, subsequently driving treatment demand. The rapid development of novel therapeutic approaches, including targeted therapies, immunotherapies, and personalized medicine based on genetic profiling, is expanding treatment possibilities and improving patient outcomes. However, the market faces substantial restraints including the extremely high costs associated with brain tumor treatments, which often require prolonged multi-modal therapy approaches, specialized equipment, and extended hospitalization periods that create financial barriers for patients and healthcare systems.

The blood-brain barrier presents a significant biological challenge, limiting drug delivery effectiveness and reducing therapeutic options, while the complex anatomical location of brain tumors makes surgical interventions inherently risky and sometimes impossible. Stringent regulatory approval processes for new therapies, coupled with the relatively small patient population for rare brain tumor types, create additional challenges for pharmaceutical companies.

Key Features of the Study

  • This report provides in-depth analysis of the global brain tumor treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global brain tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered in this study include F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc., Pfizer Inc., Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca PLC, y-Mabs Therapeutics Inc., Emcure Pharmaceuticals Ltd., NextSource Pharmaceuticals LLC, and Daiichi Sankyo Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global brain tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain tumor treatment market

Market Segmentation

  • Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
    • Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
    • Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
    • Targeted Therapy (e.g., molecularly targeted small molecules)
    • Immunotherapy (e.g., checkpoint inhibitors, CAR T therapies)
    • Other Therapies (e.g., tumor treating fields, gene therapy, combination modalities)
  • Tumor Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
    • Metastatic/Secondary Brain Tumors
    • Meningioma
    • Pituitary Tumors
    • Other Tumor Types (e.g., oligodendroglioma, ependymoma)
  • Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
    • Alkylating Agents
    • Antimetabolites
    • Monoclonal Antibodies
    • Small Molecule Inhibitors
    • Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Male
    • Female
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals and Integrated Cancer Centers
    • Ambulatory Surgical/Outpatient Centers
    • Specialty Clinics (neuro oncology clinics)
    • Home Care/Remote Care Settings (where applicable)
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals plc
    • Sun Pharmaceutical Industries Ltd.
    • Johnson and Johnson
    • Viatris Inc.
    • Hikma Pharmaceuticals plc
    • Aurobindo Pharma Ltd.
    • Endo International plc
    • Mylan N.V. (now Viatris)
    • Merck KGaA
    • Bristol Myers Squibb Company
    • Grunenthal GmbH
    • Sanofi S.A.
    • AbbVie Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Brain Tumor Treatment Market, By Treatment Modality
    • Global Brain Tumor Treatment Market, By Tumor Type
    • Global Brain Tumor Treatment Market, By Drug Class
    • Global Brain Tumor Treatment Market, By Age Group
    • Global Brain Tumor Treatment Market, By Gender
    • Global Brain Tumor Treatment Market, By End User
    • Global Brain Tumor Treatment Market, By Distribution Channel
    • Global Brain Tumor Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Brain Tumor Treatment Market, By Treatment Modality, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Targeted Therapy (e.g., molecularly targeted small molecules)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Immunotherapy (e.g., checkpoint inhibitors, CART therapies)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Therapies (e.g., tumortreating fields, gene therapy, combination modalities)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Brain Tumor Treatment Market, By Tumor Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Metastatic/Secondary Brain Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Meningioma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pituitary Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Tumor Types (e.g., oligodendroglioma, ependymoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Brain Tumor Treatment Market, By Drug Class, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Alkylating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • SmallMolecule Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Brain Tumor Treatment Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Brain Tumor Treatment Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Brain Tumor Treatment Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Integrated Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical/Outpatient Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics (neurooncology clinics)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Care/Remote Care Settings (where applicable)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Brain Tumor Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Brain Tumor Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mallinckrodt Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson and Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aurobindo Pharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Endo International plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mylana€¯N.V. (now Viatris)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mercka€¯KGaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BristolMyers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Grunenthal GmbH
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us